Document And Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Mar. 31, 2022 |
Jul. 29, 2022 |
Sep. 30, 2021 |
|
| Cover [Abstract] | |||
| Entity Registrant Name | ACASTI PHARMA INC. | ||
| Entity Incorporation, State or Country Code | Z4 | ||
| Entity Tax Identification Number | 98-1359336 | ||
| Entity Central Index Key | 0001444192 | ||
| Current Fiscal Year End Date | --03-31 | ||
| Entity File Number | 001-35776 | ||
| Entity Address, Address Line One | 3009 boul. de la Concorde East, Suite 102 | ||
| Entity Address, City or Town | Laval | ||
| Entity Address, State or Province | QC | ||
| Entity Address, Country | CA | ||
| Entity Address, Postal Zip Code | H7E 2B5 | ||
| City Area Code | 450 | ||
| Local Phone Number | 687-2262 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Emerging Growth Company | false | ||
| Entity Small Business | true | ||
| Entity Interactive Data Current | Yes | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity Common Stock, Shares Outstanding (in shares) | 44,494,193 | ||
| Entity Public Float | $ 25,942,990 | ||
| Entity Shell Company | false | ||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Mar. 31, 2022 | ||
| Document Fiscal Year Focus | 2022 | ||
| Document Fiscal Period Focus | FY | ||
| Amendment Flag | true | ||
| Title of 12(b) Security | Common Shares, no par value per share | ||
| Security Exchange Name | NASDAQ | ||
| No Trading Symbol Flag | true | ||
| Auditor Firm ID | 85 | ||
| Auditor Location | KPMG LLP | ||
| Auditor Name | Montréal, QC, Canada | ||
| Amendment Description | Acasti Pharma Inc. (the “Company”, “we”, “our” and “us”) is filing this Amendment No. 1 to Annual Report on Form 10-K (this “Amendment No. 1”) to amend its Annual Report on Form 10-K for the fiscal year ended March 31, 2022, as originally filed with the U.S. Securities and Exchange Commission, or the SEC, on June 21, 2022 (the “Original Form 10-K”), to include the information required by Items 10 through 14 of Part III of Form 10-K (the “Part III Information”). The Part III Information was previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K, which provides that in the event our definitive proxy statement is not filed with the SEC within 120 days after the end of the fiscal year covered by the Original Form 10-K, the information in Part III may be incorporated by reference from an amendment to the Original Form 10-K filed no later than 120 days after the end of the fiscal year covered by the Original Form 10-K. Because we do not anticipate that our definitive proxy statement will be filed within 120 days after the fiscal year covered by the Original Form 10-K, we are filing this Amendment to include the Part III Information. This Amendment hereby amends the cover page, Part III, Items 10 through 14, and Part IV, Item 15 of the Original Form 10-K. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, new certifications by our principal executive officer and principal financial officer are filed as exhibits to this Amendment. This Amendment does not amend or otherwise update any other information in the Original Form 10-K. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K and with our subsequent filings with the SEC. |